NN-7769 is a monoclonal antibody commercialized by Novo Nordisk, with a leading Phase III program in Hemophilia A (Factor VIII Deficiency). According to Globaldata, it is involved in 7 clinical trials, of which 3 were completed, and 4 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of NN-7769’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Net Present Value Model: Novo Nordisk AS's NN-7769

Buy the Model

Data Insights

The gold standard of business intelligence.

Find out more

The revenue for NN-7769 is expected to reach an annual total of $170 mn by 2036 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

NN-7769 Overview

NN-7769 is under development for the treatment of hemophilia A. It is administered through subcutaneous route of administration. The drug candidate is a bi-specific monoclonal antibody being developed based on Duobody platform. The drug candidate acts as a bridging factor between factor IXa (FIXa) and factor X (FX).

Novo Nordisk Overview

Novo Nordisk, a subsidiary of Novo Holdings AS, is a healthcare company focused on discovering, developing, and manufacturing of innovative biological medicines. It focuses on advancing drugs for the treatment of diabetes and other serious chronic conditions, including hemophilia, human growth hormone (HGH) disorders, rare blood and rare endocrine diseases, and obesity. The company’s portfolio includes pre-filled delivery systems for insulin; glucagon hypokit; cartridge; needles; vials; insulin; estradiol for hormone replacement; recombinant drugs for hemophilia; glucagon; and oral antidiabetic agents. The company markets its products through subsidiaries in North America, Europe, Asia, Latin America, Africa, the Middle East and Australia. Novo Nordisk is headquartered in Bagsvaerd, Denmark.
The company reported revenues of (Danish Krone) DKK176,954 million for the fiscal year ended December 2022 (FY2022), an increase of 25.7% over FY2021. In FY2022, the company’s operating margin was 42.3%, compared to an operating margin of 41.7% in FY2021. In FY2022, the company recorded a net margin of 31.4%, compared to a net margin of 33.9% in FY2021. The company reported revenues of DKK58,731 million for the third quarter ended September 2023, an increase of 8.2% over the previous quarter.

For a complete picture of NN-7769’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.